About the Authors
- Jocelyn E Mackie
- Andrew D Taylor
- David L Finegold
- Abdallah S Daar
- Peter A Singer
-
*To whom correspondence should be addressed. E-mail: peter.singer@utoronto.ca
Competing Interests
The funders and study companies did not participate in the writing or submission of this article. Researchers on the project team have had prior relationships with some of the companies studied: the Centre in Toronto has received research support from Merck and Co., and subsequent to this study, from the Oxford Health Alliance (of which Novo Nordisk is a founding member). Peter Singer has received consulting funds from Merck Frosst, and subsequent to this study, from Genzyme Canada.